Welcome to TellBio
Freeing patients from the tyranny of cancer™
About Us
TellBio Inc. is a development stage biotechnology company with the goal to revolutionize the detection and treatment of cancer through its unique and proprietary circulating tumor cells (CTCs) technology platform, the TellDx CTC System. TellBio’s vision is to free patients and their families from the tyranny of cancer.
The foundation of the TellBio’s approach – isolation of and targeting CTCs – is exclusively licensed from Massachusetts General Hospital and is based on decades of academic and clinical research.
A diagnostics solution that isolates circulating tumor cells (CTCs).
TellDx CTC System
The TellDx CTC System offers a unique opportunity to detect and monitor cancer progression via a best-in-class microfluidic diagnostic tool.
Diagnostics platform that detects circulating tumor cells (CTCs). The TellDx platform is currently deployed as a research tool at centers of excellence around the world.
Therapeutics platform that generates novel anti-cancer drugs by leveraging the proprietary knowledge derived from the study of CTCs.
Diagnostics platform that isolates circulating tumor cells (CTCs). The TellDx platform is currently deployed as a research tool at centers of excellence around the world.
Unmet Medical Need
- Early detection of cancer progression is in its infancy
- Monitoring cancer metastasis is limited to imaging and invasive biopsies
- Targeted therapies are insufficient to eradicate metastases
Differentiation
- Detection of viable CTCs via the TellDx platform is agnostic of the primary solid tumor
- Revenue-generating biotechnology company
Our story
Where the name TellBio came from
Inspired by the legend of William Tell, a 14th century marksman, who saved his child and delivered his people from a tyrant oppressing them…
TellBio’s mission is to optimize the lives of people with cancer and free them from the tyranny of metastatic disease.
News
Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-223
Press Release - March 27, 2024
